Can the pharmaceutical industry reduce attrition rates?
暂无分享,去创建一个
[1] I. Kola,et al. An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling. , 1999, Molecular medicine today.
[2] I. Kola,et al. Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[3] Scott Myers,et al. Drug discovery—an operating model for a new era , 2001, Nature Biotechnology.
[4] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[5] P. Ma,et al. Value of novelty? , 2002, Nature Reviews Drug Discovery.
[6] P. Ma,et al. Oncology's trials , 2003, Nature Reviews Drug Discovery.
[7] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[8] 2003 approvals: a year of innovation and upward trends , 2004, Nature Reviews Drug Discovery.